^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Published date:
    08/26/2013
    Excerpt:
    Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non small cell lung cancer with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    Precision Medicine Online
    Title:

    NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC

    Published date:
    05/11/2023
    Excerpt:
    The UK's National Institute for Health and Care Excellence (NICE) on Thursday recommended Novartis' BRAF/MEK inhibitor combination, Tafinlar plus Mekinist (dabrafenib plus trametinib), as a first-line option for advanced non-small cell lung cancer patients in England whose tumors harbor BRAF V600 mutations.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

    Excerpt:
    ...- Histologically or cytologically confirmed diagnosis of Stage IV NSCLC (according to AJCC 8th edition) that is BRAF V600E mutation-positive by local test result from a qualified assay (NMPA and/or MOH-approved)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

    Excerpt:
    ...- Presence of a BRAF V600E mutation in lung cancer tissue....